Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Jan 14;16(1):e0245055. doi: 10.1371/journal.pone.0245055

Impact of altitude on COVID-19 infection and death in the United States: A modeling and observational study

Kenton E Stephens 1, Pavel Chernyavskiy 2, Danielle R Bruns 1,3,*
Editor: Jeffrey Shaman4
PMCID: PMC7808593  PMID: 33444357

Abstract

Background

COVID-19, the disease caused by SARS-CoV-2, has caused a pandemic, sparing few regions. However, limited reports suggest differing infection and death rates across geographic areas including populations that reside at higher elevations (HE). We aimed to determine if COVID-19 infection, death, and case mortality rates differed in higher versus low elevation (LE) U.S. counties.

Methods

Using publicly available geographic and COVID-19 data, we calculated per capita infection and death rates and case mortality in population density matched HE and LE U.S. counties. We also performed population-scale regression analysis to investigate the association between county elevation and COVID-19 infection rates.

Findings

Population density matching of LA (< 914m, n = 58) and HE (>2133m, n = 58) counties yielded significantly lower COVID-19 cases at HE versus LE (615 versus 905, p = 0.034). HE per capita deaths were significantly lower than LE (9.4 versus 19.5, p = 0.017). However, case mortality did not differ between HE and LE (1.78% versus 1.46%, p = 0.27). Regression analysis, adjusted for relevant covariates, demonstrated decreased COVID-19 infection rates by 12.82%, 12.01%, and 11.72% per 495m of county centroid elevation, for cases recorded over the previous 30, 90, and 120 days, respectively.

Conclusions

This population-adjusted, controlled analysis suggests that higher elevation attenuates infection and death. Ongoing work from our group aims to identify the environmental, biological, and social factors of residence at HE that impact infection, transmission, and pathogenesis of COVID-19 in an effort to harness these mechanisms for future public health and/or treatment interventions.

Introduction

Coronavirus disease 2019 (COVID-19) is an illness caused by novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that emerged in Wuhan, China in late 2019 and has rapidly proceeded to cause a pandemic. COVID-19 has reached nearly every corner of the globe and affects every demographic. While individual risk factors such as age, male sex, hypertension, diabetes, and heart disease have been previously identified [1], COVID-19 also appears to have unequal infection rates and mortality across geographical regions, suggesting that a combination of social, environmental, and biological risk factors may affect transmission, infection, morbidity, and mortality. One such environmental factor which has attracted interest over the past few months and which our group has significant interest and expertise, is high altitude residence.

The first report of high altitude regions and COVID-19, published in April 2020, demonstrated lower infection rates and mortality in high altitude regions in Tibet, Peru, and Ecuador in comparison to low-altitude regions in the same countries [2]. Since then, subsequent reports have shown no impact of altitude on infection [3], attenuated infection at high altitude [4,5], while others have suggested that COVID-19 infection rates are lower at high altitude, but mortality is not [6], and worsened mortality in high altitude regions [7]. These conflicting findings are likely due to differences in population density, lack of control for population density in the statistical model, as well as due to limited reports of cases and deaths in sparsely populated and/or remote high altitude locations. Approaching the hypothesis that high altitude residence is protective against COVID-19 may require multiple quantitative epidemiology perspectives. We set out to test the hypothesis that higher elevations (HE) attenuates COVID-19 infection rates using two distinct approaches: matching of HE and low elevation (LE) regions and using a statistical modeling approach. We performed U.S. county-level regression analysis, which allowed us to examine the contribution of county centroid elevation in the presence of other risk factors and county-specific latent spatial effects. In an effort to reflect the temporal dynamics of the pandemic, we evaluated the association of county centroid elevation with incidence recorded over the previous 30, 90, and 120 days. To our knowledge, this is the first systematic, population-density adjusted epidemiologic investigation of the impact of altitude on COVID-19 disease infection, deaths, and mortality rates in the U.S. Further, we discuss the biological, social, and environmental contributors to COVID-19 infection, transmission, and pathogenesis, and how these factors are impacted by residence at high altitude.

Methods

Matching of high and low altitude counties

High elevation was defined as average elevation greater than 2,133m above sea level. Low elevation was defined as less than 914m. This distinction purposefully omitted locations of moderate elevation, facilitating robust comparisons. Previous reports of COVID and altitude have utilized definitions of higher than 2,800m; however, in the U.S., only 14 counties have an average elevation above this cutoff. Therefore, to reduce statistical noise in the data and due to known clinical and physiological impact of altitude on human physiology at and above 2,000m [8], we used a less restrictive definition. A total of 58 counties above 2,133m were identified. We then matched 58 LE counties as controls. HE and LE counties were matched based on population densities: each HE county was matched to a LE county with a population density between 0.75 and 1.25 times the density of the HE county (0.75 < LE population density/HE population density < 1.25). Population of each county was obtained from federal estimates for the 2019 population based on the 2010 U.S. Census. County area was gathered from the U.S. Census Bureau’s 2011 compendium of county areas in square miles. Population density was defined as 2011 population divided by county area in square miles, yielding a density measured in persons per square mile.

COVID-19 cases and deaths were obtained from state and county public health department websites at the end of the business day (AKDT time) on 8/7/2020. Per capita infection rates were calculated using the formula county COVID-19 cases divided by the estimated 2019 county population and then multiplying by 100,000. Per capita death rates were calculated in an identical manner. County COVID-19 mortality rates were calculated by dividing the cumulative county deaths due to COVID-19 by cumulative COVID-19 infections. In cases where counties reported zero COVID-19 cases, the case mortality was set equal to zero.

Infection, death, and case mortality rates were analyzed by one-sided Student’s t-test, with an alpha level of 0.05. Significance of correlation coefficients were also calculated. Data are presented as means ± standard error of the mean.

Statistical modeling

In addition to the matched case-count analysis, we estimated U.S. county-level regression models, with COVID-19 incidence rates as the outcome. To account for different temporal patterns during the pandemic, we performed our analysis on cases collected over 30, 90, and 120 days prior to 8/27/2020. Case counts were collected from the COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University [9], which are updated daily. Our data covers counties in the 48 contiguous U.S. states and the District of Columbia. County population at-risk and the number of households were obtained from the decennial U.S. census.

As a proxy for residence at high altitude, we computed the elevation in meters of county centroids (geometric centers) using the elevatr software package [10] in R 4.0 [11]. Although centroids do not necessarily represent the location of population within each county, a map of county centroids accurately reflects the variability in elevation around the United States (S1 Fig). Centroid elevations range from -71m to 3401m, with mean elevation of 430m and median elevation of 274m. In addition to county centroid elevation and total county population as an offset term, each model contained the following covariates: 1) 9-level USDA 2013 Rural-Urban Continuum Codes (USDA RUCC), where higher-numbered categories indicate increasingly rural environments; 2) average number of persons per household, computed as county population/number of households; 3) interaction of persons per household and USDA Rural-Urban Continuum Codes; 4) independent state random effects; and 5) spatially-correlated county random effects. All estimation was performed using Negative-Binomial and Tweedie-Poisson Generalised Additive Models within the mgcv R package [12]. For more details about the statistical analysis, the reader is directed to Supplementary Statistical Methods. Data sets for analysis and additional S1 File, including R code to reproduce our analyses, are available at https://github.com/pchernya/Covid_Elev.

Results

High and low altitude county matching results

Of 3,141 counties in the United Sates, 58 counties from eight states were identified as HE. 58 LE counties of matched population density from 20 states were chosen for comparison. HE and LE county matching by population density and discrimination by altitude was successful (Table 1). Graphical representation of county altitudes is shown in Fig 1.

Table 1. Matched high and low altitude county demographics.

Low Elevation (n = 58) Elevation (m) Population Density (persons/mile2)
Maximum 903 485,493 775
Minimum 0 654 0.51
Mean 366 31,398 37.6
High Elevation (n = 58)
Maximum 3,425 582,881 762
Minimum 2,141 728 0.5
Mean 2,536 38,603 37.3

Fig 1. High and low altitude counties by elevation (m).

Fig 1

Red lines mark the definition of high altitude (>2133m) and low altitude (<914m).

Average HE county COVID-19 infection rate was 615 ± 71 cases per 100,000 population, which was statistically significantly lower than the LE county average infection rate of 907 ± 141 (p = 0.034; Fig 2A). Infection rate did not correlate with population density (r = 0.01 and 0.22 for either HE or LE, Fig 2B). Average HE county COVID-19 death rate were 9 ± 2 per 100,000 population and statistically significantly lower than average LE county 19 ± 4 (p = 0.017; Fig 2C). Deaths per 100,000 showed a positive association with population density at both HE and LE locations (r = 0.26 and 0.26, respectively). Even when removing HE (n = 27) and LE (n = 31) counties with infection and death counts of zero, per capita infection and death rates remained significantly lower at HE (p = 0.002 and p = 0.001; S2 Fig). Average COVID-19 case mortality between HE and LE counties was not statistically significantly different at 1.78 ± 0.2% and 1.46 ± 0.4%, respectively (p = 0.267; Fig 2C).

Fig 2. COVID-19 infection and death in matched high and low elevation counties.

Fig 2

A) Mean COVID-19 cumulative per capita incidence per 100,000 population B) and lack of correlation with population density. C) Mean COVID-19 cumulative per capita death per 100,000 population D) positively correlated with population density at both high- and low-elevation counties. E) COVID-19 case mortality in high and low elevation counties of similar population density. N = 58 for both high elevation and low elevation counties. *p<0.05 by one-sided t-test.

Modeling results

Our models explain a large portion of variability in COVID-19 incidence with model-based estimates of 80.2%, 84.0%, and 79.7%, for models fit to 120-day, 90-day, and 30-day case counts, respectively. Adjusted for other covariates, incidence rates decreased by 11.72% (16.07%, 7.14%), 12.01% (16.10%, 7.72%), and 12.82% (17.18%, 8.23%) per 495 meters of elevation on average, for cases recorded over the previous 120, 90, and 30 days, respectively. To investigate the potential of a non-linear association between elevation and incidence, we fitted models that included a general smooth function of elevation for each of the three outcome variables. For incidence over 120 days (Fig 3A) and 90 days (Fig 3B), the relationship with elevation is approximately linear from the minimum elevation through the point 3SD above mean elevation (1915m). For counties with centroids above 1915m, uncertainty grows and the strength of association between elevation and incidence diminishes. For incidence over 30 days (Fig 3C), evidence of a non-linear relationship is weak and a model with a linear relationship between elevation and incidence is preferred (S1 Table).

Fig 3. U.S. county-level regression models, with incident COVID-19 cases as the outcome.

Fig 3

A) 120-day incidence decreased by 11.72% (16.07%, 7.14%) on average, B) 90-day incidence by 12.01% (16.10%, 7.72%) on average, and C) 30-day incidence decreased by 12.82% (17.18%, 8.23) on average per 495 meters of elevation on average, after adjustment for covariates.

Discussion

The COVID-19 pandemic has rapidly reached countries and individuals from all demographics. However, some preliminary reports suggest that environmental factors such as altitude may impact disease infection and pathogenesis. To test the hypothesis that residence at high altitude attenuates disease infection and outcome, we used publicly available data to determine infection, death, and case mortality rates in U.S. counties of high and low altitude. For the first time, we provide rigorously population-matched and altitude-delineated analysis of COVID-19 outcomes. Cumulative per capita COVID-19 incidence and death rates were significantly lower in HE counties in comparison to LE counties, with similar case mortality rates. Additionally, we offer complimentary evidence in favor of our hypothesis using a county-level regression model. To our knowledge, our model is the first to examine the effects of elevation in the presence of state and county effects that control for latent legislative, environmental, and social risk factors, such as adherence to public health guidelines, population demographics, and attributes of the built environment. Our analysis suggests that elevation is inversely associated with incidence through an elevation of 1915m (i.e., 3SD above mean elevation), with little-to-no association as elevation increases further. Two of our models suggest a slight increase in risk at elevations higher than 1915m, which may be an artifact of sparsity in the data, or the fact that many tourist destinations (e.g., ski resorts) that experienced early COVID-19 outbreaks tend to be located in those counties.

Together, these analyses offer evidence that residence at HE attenuates SARS CoV-2 infection and thus death rates, without altering disease pathogenesis such that once infected, risk of death (mortality) is similar at HE versus LE. The differences in COVID-19 outcomes at higher elevations are likely multifactorial and affect transmission, infection, and pathogenesis (Fig 4). Furthermore, these factors likely stem from environmental, biological, as well as social and policy-level differences. Future efforts aimed at understanding these factors and how they differ in populations of residence at higher elevations are critical for modification of disease outcomes.

Fig 4. Summary of proposed mechanisms of difference in COVID-19 infection, transmission, and pathogenesis at high altitude.

Fig 4

Factors which may impact COVID-19 infection and death at high altitude include host, environmental, viral, and healthcare factors.

SARS-CoV-2 transmission at high altitude

Transmission of SARS-CoV-2 occurs through respiratory droplets, aerosols, and fomites [13]. Several factors impact viral survival outside of the host, including temperature, humidity, and type and intensity of UVB light. SARS-CoV-2 infectivity is attenuated with increasing temperature and humidity [14] as well as with higher intensity of UVB [15]. At higher altitudes, temperature and relative humidity decrease, while intensity of UVB light increases [16]. On the other hand, greater sunlight leads to higher vitamin D, which increases host T-cell mediated protection to viral pathogens [17]. Limited and discrepant reports suggest that temperature, humidity, vitamin D, and UV light contribute modestly to SARS-CoV-2 transmission [1821], but these reports lack consensus and to our knowledge have not been extrapolated to specific geographic locations such as altitude. Since many environmental variables change with altitude and their respective effects on SARS-CoV-2 infectivity can be at odds, the sum effect of increasing altitude on COVID-19 transmission is complex and requires further study to determine which environmental factors have the greatest effect on viral transmission.

SARS-CoV-2 infection at high altitude

The interaction between infectious agent and host has long been known to be impacted by environmental factors. Hypoxia was among the first such studied environmental factors, with reports in the early 1950’s that mice housed with reduced atmospheric pressure at simulated altitude demonstrated attenuated viral load and mortality [22,23]. With specific regard to SARS-CoV-2, expression of ACE2, the receptor used for cellular entry by SARS-CoV-2 [24,25] is altered in response to hypoxia or simulated altitude. However, these data are limited and inconsistent. While some reports found decreased in ACE2 expression in human pulmonary artery smooth muscle cells placed in a hypoxic environment (2% O2) for 12 days [26] and decreased ACE2 in right ventricular tissue from rats in hypobaric hypoxia (4800 m) for 28 days [27], others have reported ACE2 upregulation in hypoxic environments [28,29]. In addition to conflicting tissues, altitude/hypoxia exposure, and outcomes, none of these pre-clinical mechanistic investigations have utilized models which reside at altitude, but rather have instead utilized short-term ascent to altitude. Thus, there is a critical need to understand the impact of chronic hypoxia/high altitude on ACE2 expression as a mechanism of SARS-CoV-2 infection. Preliminary data from our lab suggests that mice that reside at HE (1915m) for several generations have significantly lower cardiac ACE2 expression than animals raised at sea level. Further study of ACE2 expression in the lungs, respiratory tract, and in other tissues is essential to determining if and to what degree ACE2 expression (and other SARS-CoV-2 receptors) changes in response to hypoxia (altitude), and if this confers susceptibility or protection to COVID-19 infection.

Pathogenesis of SARS-CoV-2 and COVID-19 at high altitude

Our data demonstrate that HA-mediated attenuation of infection results in lower death rates with similar case mortality, implying that following infection, disease pathogenesis or severity is not attenuated by elevation. However, even in locations where COVID-19 testing is adequate, asymptomatic cases are likely largely undetected. Thus, it is possible that residence at higher elevation favors asymptomatic infection, due to host adaptation, presence of comorbidities, or other factors. COVID-19 has disproportionately affected people of color, the elderly, and those with pre-existing conditions such as diabetes and obesity [1]. Residents of HE are less likely to be obese than lowlanders [30], likely both through physiological regulation of metabolism at hypoxia, but also due to lifestyle and social factors such as physical activity. Demographic reports of high versus low altitude locations are warranted, given some suggestion that older individuals, especially those with comorbid conditions, are likely to relocate to lower altitude due to reasons of poor health [31]. On the other hand, host adaptations to living at and side effects of altitude may provide protection against COVID-19 disease. Such defenses include attenuation of comorbidities as discussed above, tolerance to hypoxemia given lower O2 saturations at altitude, and others. Whether these host factors impact infection risk also remain unknown and likely could contribute to the attenuated infections observed in our study. Lastly, environmental factors which impact pathogenesis likely contribute to outcomes, such as air quality. Pollution is a proposed susceptibility factor for COVID-19 [32] and may differ at higher elevations, especially during wildfire season in the western United States. Together, it is clear that etiology, pathogenesis, and outcomes of COVID-19 differ at higher elevation locations, likely a result of complex interplay between these factors.

Our study has several limitations. We report cumulative as well as 30, 90, and 120-day infection rates as of late August 2020. As such, our data largely reflect the early pandemic and the summer months in the United States. Given the known association between seasonality and COVID-19 transmission, we suggest that future work elucidate the interaction between season and high altitude. Elevation of county centroids only serves as a proxy variable and does not necessarily reflect the elevation of where residents reside in any given county. Our data is drawn from population-level data sources and we do not have access to individual-level data. Individual-level analyses would permit control for comorbid conditions, COVID-19 hospitalizations and complications, and would almost certainly yield insight into potential mechanisms by which altitude affects infection and survival. Analyses of the targeted mechanisms by which altitude protects against COVID-19 infection are critical for understanding of SARS-CoV-2 infection, transmission, and pathogenesis, and for design of interventions which attenuate poor outcomes. While we demonstrate that residence at higher elevations is protective against COVID-19 infection and death, we also caution that these data are associations drawn from residents of altitude, rather than acute ascent. We strongly suggest that future work is needed to understand how high altitude impacts COVID-19. Public health guidance and preventive measures must continue to be practiced by high altitude residence and visitors.

Supporting information

S1 Fig. Unprojected choropleth map of U.S. county centroids colored by elevation in meters.

Elevation patterns based on county centroids closely represent elevation patterns of the continental U.S.

(DOCX)

S2 Fig. COVID-19 infection and death in matched high and low altitude counties with removal of counties with infection and death counts of zero.

A) Mean COVID-19 cumulative per capita incidence per 100,000 population. B) Mean COVID-19 cumulative per capita death per 100,000 population. C) COVID-19 case mortality in high and low altitude counties of similar population density. N = 33 for high altitude and N = 26 for low altitude counties. *p<0.05 by one-sided t-test.

(DOCX)

S1 Table. Akaike Information Criterion (AIC) and percent deviance explained in parentheses for the statistical models considered.

Smaller AIC and larger percent deviance explained constitutes the preferred model.

(DOCX)

S1 File

(DOCX)

Acknowledgments

The authors thank Tim Robinson and Emily Schmitt.

Data Availability

Data are available in GitHub: https://github.com/pchernya/Covid_Elev.

Funding Statement

This work was supported by Wyoming-WWAMI and NIH/NIA K01 AG058810 (DRB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.CDC. Novel Coronavirus Reports: Morbidity and Mortality Weekly Report (MMWR). 2020.
  • 2.Arias-Reyes C, Zubieta-DeUrioste N, Poma-Machicao L, Aliaga-Raduan F, Carvajal-Rodriguez F, Dutschmann M, et al. Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude? Respir Physiol Neurobiol. 2020;277:103443 Epub 2020/04/26. 10.1016/j.resp.2020.103443 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Castagnetto JM, Segovia-Juarez J, Gonzales GF. Letter to the Editor: COVID-19 Infections Do Not Change with Increasing Altitudes from 1,000 to 4,700 m. High Alt Med Biol. 2020. Epub 2020/10/16. 10.1089/ham.2020.0173 . [DOI] [PubMed] [Google Scholar]
  • 4.Intimayta-Escalante C, Rojas-Bolivar D, Hancco I. Letter to the Editor: Influence of Altitude on the Prevalence and Case Fatality Rate of COVID-19 in Peru. High Alt Med Biol. 2020. Epub 2020/08/18. 10.1089/ham.2020.0133 . [DOI] [PubMed] [Google Scholar]
  • 5.Lin EM, Goren A, Wambier C. Letter to the Editor: Environmental Effects on Reported Infections and Death Rates of COVID-19 Across 91 Major Brazilian Cities. High Alt Med Biol. 2020. Epub 2020/10/09. 10.1089/ham.2020.0168 . [DOI] [PubMed] [Google Scholar]
  • 6.Segovia-Juarez J, Castagnetto JM, Gonzales GF. High altitude reduces infection rate of COVID-19 but not case-fatality rate. Respir Physiol Neurobiol. 2020;281:103494 Epub 2020/07/18. 10.1016/j.resp.2020.103494 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Woolcott OO, Bergman RN. Mortality Attributed to COVID-19 in High-Altitude Populations. High Alt Med Biol. 2020. Epub 2020/08/21. 10.1089/ham.2020.0098 . [DOI] [PubMed] [Google Scholar]
  • 8.Barry PW, Pollard AJ. Altitude illness. BMJ. 2003;326(7395):915–9. Epub 2003/04/26. 10.1136/bmj.326.7395.915 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–4. Epub 2020/02/23. 10.1016/S1473-3099(20)30120-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ha Tarak. elevatr: Access Elevation Data from Various APIs. Washington, DC: U.S. EPA Office of Research and Development; 2017. [Google Scholar]
  • 11.Team RDC. R: A language and environment for statitistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. [Google Scholar]
  • 12.Wood S. Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models. Journal of the Royal Statistical Society (B) 2010;73(1):3–36. [Google Scholar]
  • 13.Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199–207. Epub 2020/01/30. 10.1056/NEJMoa2001316 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Biryukov J, Boydston JA, Dunning RA, Yeager JJ, Wood S, Reese AL, et al. Increasing Temperature and Relative Humidity Accelerates Inactivation of SARS-CoV-2 on Surfaces. mSphere. 2020;5(4). Epub 2020/07/03. 10.1128/mSphere.00441-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ratnesar-Shumate S, Williams G, Green B, Krause M, Holland B, Wood S, et al. Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces. J Infect Dis. 2020;222(2):214–22. Epub 2020/05/21. 10.1093/infdis/jiaa274 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.WHO. Ultraviolet radiation and health. https://www.who.int/uv/uv_and_health/en/#:~:text=Altitude%E2%80%94at%20higher%20altitudes%2C%20a,otherwise%20reach%20the%20Earth’s%20surface.
  • 17.Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020;12(4). Epub 2020/04/08. 10.3390/nu12040988 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sehra ST, Salciccioli JD, Wiebe DJ, Fundin S, Baker JF. Maximum Daily Temperature, Precipitation, Ultra-Violet Light and Rates of Transmission of SARS-Cov-2 in the United States. Clin Infect Dis. 2020. Epub 2020/05/31. 10.1093/cid/ciaa681 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Yao Y, Pan J, Liu Z, Meng X, Wang W, Kan H, et al. No association of COVID-19 transmission with temperature or UV radiation in Chinese cities. Eur Respir J. 2020;55(5). Epub 2020/04/10. 10.1183/13993003.00517-2020 Jinhua Pan has nothing to disclose. Conflict of interest: Zhixi Liu has nothing to disclose. Conflict of interest: Xia Meng has nothing to disclose. Conflict of interest: Weidong Wang has nothing to disclose. Conflict of interest: Haidong Kan has nothing to disclose. Conflict of interest: Weibing Wang has nothing to disclose. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ran J, Zhao S, Han L, Liao G, Wang K, Wang MH, et al. A Re-analysis in Exploring the Association between Temperature and COVID-19 Transmissibility: An Ecological Study with 154 Chinese Cities. Eur Respir J. 2020. Epub 2020/07/08. 10.1183/13993003.01253-2020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Calvo MS. High-altitude living and vitamin D: factors associated with viral risk? Am J Clin Nutr. 2020;112(4):915–6. Epub 2020/09/06. 10.1093/ajcn/nqaa250 . [DOI] [PubMed] [Google Scholar]
  • 22.Berry LJ, Mitchell RB, Rubenstein D. Effect of acclimatization to altitude on susceptibility of mice to influenza A virus infection. Proc Soc Exp Biol Med. 1955;88(4):543–8. Epub 1955/04/01. 10.3181/00379727-88-21646 . [DOI] [PubMed] [Google Scholar]
  • 23.Gordon FB, Gillmore JD. Parabarosis and experimental infections. I. Effect of varying O2 tensions on influenza virus infection in mice. Aerosp Med. 1974;45(3):241–8. Epub 1974/03/01. . [PubMed] [Google Scholar]
  • 24.Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4. Epub 2003/12/04. 10.1038/nature02145 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. Epub 2020/02/03. 10.1016/S0140-6736(20)30251-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zhang R, Wu Y, Zhao M, Liu C, Zhou L, Shen S, et al. Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2009;297(4):L631–40. Epub 2009/07/14. 10.1152/ajplung.90415.2008 . [DOI] [PubMed] [Google Scholar]
  • 27.Dang Z, Su S, Jin G, Nan X, Ma L, Li Z, et al. Tsantan Sumtang attenuated chronic hypoxia-induced right ventricular structure remodeling and fibrosis by equilibrating local ACE-AngII-AT1R/ACE2-Ang1-7-Mas axis in rat. J Ethnopharmacol. 2020;250:112470 Epub 2019/12/22. 10.1016/j.jep.2019.112470 . [DOI] [PubMed] [Google Scholar]
  • 28.Hampl V, Herget J, Bibova J, Banasova A, Huskova Z, Vanourkova Z, et al. Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia. Physiol Res. 2015;64(1):25–38. Epub 2014/09/07. 10.33549/physiolres.932861 . [DOI] [PubMed] [Google Scholar]
  • 29.Joshi S, Wollenzien H, Leclerc E, Jarajapu YP. Hypoxic regulation of angiotensin-converting enzyme 2 and Mas receptor in human CD34(+) cells. J Cell Physiol. 2019;234(11):20420–31. Epub 2019/04/17. 10.1002/jcp.28643 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Voss JD, Allison DB, Webber BJ, Otto JL, Clark LL. Lower obesity rate during residence at high altitude among a military population with frequent migration: a quasi experimental model for investigating spatial causation. PLoS One. 2014;9(4):e93493 Epub 2014/04/18. 10.1371/journal.pone.0093493 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Regensteiner JG, Moore LG. Migration of the elderly from high altitudes in Colorado. JAMA. 1985;253(21):3124–8. Epub 1985/06/07. . [PubMed] [Google Scholar]
  • 32.Frontera A, Cianfanelli L, Vlachos K, Landoni G, Cremona G. Severe air pollution links to higher mortality in COVID-19 patients: The "double-hit" hypothesis. J Infect. 2020;81(2):255–9. Epub 2020/05/25. 10.1016/j.jinf.2020.05.031 no financial support for this study. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Jeffrey Shaman

3 Nov 2020

PONE-D-20-28278

Impact of altitude on COVID-19 infection and death in the United States: a modeling and observational study

PLOS ONE

Dear Dr. Bruns,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please respond to each of the reviewer's comments on a point-by-point basis and revise the manuscript accordingly.

Please submit your revised manuscript by Dec 18 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Jeffrey Shaman

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Interesting article that further supports the role of host factors in viral spread in community. Among many of the previously published articles, there is one that found association of lower altitude and population density with lethality rates, please cite it in the discussion: 10.1089/ham.2020.0168 which only included cities above a certain population cut-off.

Another important point omitted in the discussion is that the dataset included the Summer months. As we currently know the host factors in the summer make pathogenicity extremely low compared to winter and early spring. It is ok to include summer months, however, an attenuator is present that is independent of elevation, in the last months of data collection.

Reviewer #2: The incidence of COVID-19 at high altitude is garnering an attention. The rigorous science is required for the conclusion and it has to be with cautionary as the stakes are too high especially when the conclusion tends to be lower incidence. Specific comments:

Authors have take a liberal approach in classification of altitude (in their own words). They must be taking it very seriously and it is the primary objective to map out COVID-19. So they cannot take liberal approach.

I strongly suggest authors to stratify their data in different altitudes: <500m, <1000m, <1500m, <2000m, <2500m, <3000m and >3000m for the incidence analysis.

Secondly, the altitude cut off should be re-arranged <500 as low altitude and high altitude as >2500m. Authors have found a reference that suits them. High altitude is defined >2500m.

Third, authors have to have analysis based on the altitude of residence not based on the county/province. They have to used absolute altitude of residence (born and raised altitude) of the participants (population) for the consideration. Otherwise, this is going to be a noise rather than real scientific finding.

Fourth, authors need to do better job analysing data with several variables or covariates such as population density, age/sex distribution, testing frequency/facilities, sever COVID-19 facilities, community transmission and others.

Fifth, authors have missed several key and seminal publications in this field. I would highly encourage to keep uptodate and discuss their results accordingly. They should also learn from other literature how they have analysed their data and advance in their analyses. Some of the key literature they must not miss are:

Woolcott & Bergman:

https://www.liebertpub.com/doi/full/10.1089/HAM.2020.0098

Castagnetto et al:

https://www.liebertpub.com/doi/full/10.1089/ham.2020.0173

Lin et al:

https://www.liebertpub.com/doi/full/10.1089/ham.2020.0168

Pun et al:

Lower Incidence of COVID-19 at High Altitude: Facts and Confounders

https://www.liebertpub.com/doi/10.1089/ham.2020.0114

Intimayta-Escalante et al:

https://www.liebertpub.com/doi/full/10.1089/ham.2020.0133

Calvo MS:

https://academic.oup.com/ajcn/article-abstract/112/4/915/5901951

Reviewer #3: Associations of COVID-19 cases and deaths with altitude has been the subject of a number of peer-reviewed and pre-print studies since the emergence of the pandemic. While some studies conclude that likelihood of cases and/or deaths from COVID-19 inversely correlates with high altitude, other studies have not reached the same conclusion. Few studies consider population density in their analyses, which may be a relevant parameter to normalize disease susceptibility vs clustering effects.

In line with other studies, the authors do consider population density in high-altitude (HA) vs low-altitude (LA) sites in the US, and find that HA is associated with lower COVID-19 case and death rates, independent of density. This is an interesting finding by itself.

However, in addition to physiological adaptation to HA, many other variables may impact on this apparent association, in particular co-morbidies and ethnicity. While the latter are discussed in the manuscript, it would be important that these parameters are actually analyzed as part of the study, so as to reach conclusions as the role played by these factors in the observed associations.

It would also be desirable that the authors supply the datasets used for their analyses, in a format amenable to reproduction and re-analysis by readers, including reviewers.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: carlos gustavo wambier

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jan 14;16(1):e0245055. doi: 10.1371/journal.pone.0245055.r002

Author response to Decision Letter 0


9 Nov 2020

Dear Editor and Reviewers-

While responding to revisions as requested below and in the process of making our analysis publicly available, we noticed that at the time of our initial model (August 2020), a mistake of omission had been made with respect to New York City area reporting. At the time we pulled this dataset, NYC was not reporting any confirmed cases- clearly a mistake as there must have been some cases in a population of over 8 million residents. In an effort not to misrepresent the dataset, we re-ran all statistics from 8/27 using the now amended dataset, matching the dates stated in the paper. Nothing else changed- we simply reran the model to be more representative. When we did so, our linear associations with COVID incidence per 495m at 120, 90, and 30 days changed by 0.32, 0.33, and 0.56%, respectively. While these confidence intervals changed minimally, they did change in the direction of our hypothesis- of protection at high altitude. We chose to draw the Reviewer and Editors attention to this matter in an effort to be transparent and thorough in our analysis.

We thank the reviewers for their thoughtful and constructive feedback. We are pleased the reviewers were generally enthusiastic about our work and its impact. We have made efforts to improve our manuscript, as suggested below. We hope that our work is now suitable for publication in PLOS One.

Reviewer #1: Interesting article that further supports the role of host factors in viral spread in community. Among many of the previously published articles, there is one that found association of lower altitude and population density with lethality rates, please cite it in the discussion: 10.1089/ham.2020.0168 which only included cities above a certain population cut-off.

We thank the reviewer for drawing our attention to this publication. We have referenced the work these authors did in discussing population density and altitude in the introduction.

Another important point omitted in the discussion is that the dataset included the Summer months. As we currently know the host factors in the summer make pathogenicity extremely low compared to winter and early spring. It is ok to include summer months, however, an attenuator is present that is independent of elevation, in the last months of data collection.

We agree that there may be some seasonality in the protective effect of elevation and have added text in the discussion to this effect and agree that further investigation around the presence of a seasonal effect is warranted.

While a complete update of our data and analysis is outside the scope of the current manuscript, in an effort to investigate how the change in season influenced the apparent protective effect of elevation, we re-estimated our model using cases collected over the previous 90 days as of 11/04/2020. With these updated data, the estimated linear effect (95% Confidence Interval) per 495m (1 SD) of elevation is -9.44% (-13.01%, -5.72%), which is only somewhat attenuated relative to what we originally reported. Qualitatively speaking, these updated results do not change our findings. Therefore, while future work is warranted for the mixed effects of altitude and seasonality, it does not change the significant effect reported here on altitude and COVID-19 infection.

Reviewer #2: The incidence of COVID-19 at high altitude is garnering an attention. The rigorous science is required for the conclusion and it has to be with cautionary as the stakes are too high especially when the conclusion tends to be lower incidence. Specific comments:

We agree with the review that the stakes are high, especially when our conclusion is that incidence is lower at high altitude. However, our discussion cautions readers to the conclusions drawn here- that they are associative, not causative, and that likely the benefits are only evident with residence at HA, not acute ascent. We have also amended the discussion to encourage implementation and following of public health guidelines.

Authors have take a liberal approach in classification of altitude (in their own words). They must be taking it very seriously and it is the primary objective to map out COVID-19. So they cannot take liberal approach.

Taking a rigorous approach to study the impact of high altitude on COVID-19 does not require a rigorous definition of altitude. In fact, using strict definitions of altitude has limited previous work from drawing conclusions, given the sparse population at high altitude, the lack of control for population density, and the known impact of mild altitude on disease and viral biology. Further, our modeling results support our classification of altitude, since this approach does not require discrete cut-offs, but rather calculated relative infection risk by 500m intervals. Our novel dual approach, consistent finding that HA protects against infection, and limitations of previous work support the approach that a strict cut-off of >2500m is not necessary to understand the impact of HA on disease transmission. A consensus definition of high altitude has yet to be reached- with some groups utilizing 2400m, others 2800, and some 1500m.

I strongly suggest authors to stratify their data in different altitudes: <500m, <1000m, <1500m, <2000m, <2500m, <3000m and >3000m for the incidence analysis.

While this approach has merit, it is not feasible for the paired approach we employed, since sufficient counties with population matching do not exist at these discrete intervals. However, our modeling analysis does take this discrete approach, as the protection of HA on COVID-19 incidence is reported as +/- SD (500m).

Secondly, the altitude cut off should be re-arranged <500 as low altitude and high altitude as >2500m. Authors have found a reference that suits them. High altitude is defined >2500m.

As discussed above and in the manuscript, we believe these strict cut-offs limit statistical and biological comparisons. We matched HA with LA counties based on population density, given the well-reported associations between population density and viral spread, especially at locations of HA [1]. We were unable to find comparable matches at <500m for all our HA locations, thus we used slightly higher, but still <914m. Further, our modeling analysis uses discrete 500m changes in elevation and demonstrates significant protection (11% for every 500m), even at elevations <2500m.

Third, authors have to have analysis based on the altitude of residence not based on the county/province. They have to used absolute altitude of residence (born and raised altitude) of the participants (population) for the consideration. Otherwise, this is going to be a noise rather than real scientific finding.

The reviewer is correct that absolute residence of birth and residence would be a cleaner statistical approach. However, this data does not exist in the United States. COVID-19 data is not tracked at a municipality smaller than the county-level, nor does any population-level or census data take into account birth and time of residence at HA. We do not have populations of individuals who have resided for generations at HA, such as those in Tibet and Peru. While we acknowledge this limitation in our discussion, our data are still robust enough and our effects still significant enough to capture the effect of HA on COVID-19 infection.

Fourth, authors need to do better job analysing data with several variables or covariates such as population density, age/sex distribution, testing frequency/facilities, sever COVID-19 facilities, community transmission and others.

The reviewer is correct that these covariates are significant as they relate to COVID-19 transmission and mortality. We’ve controlled for rurality, persons per household, interaction of persons per household and rurality, state effects, and spatial effects in our modeling analysis. Unfortunately, some of the other variables such as testing frequency and facilities are not available for analysis. However, we have discussed these variables as contributors in our discussion.

Fifth, authors have missed several key and seminal publications in this field. I would highly encourage to keep uptodate and discuss their results accordingly. They should also learn from other literature how they have analysed their data and advance in their analyses. Some of the key literature they must not miss are:

We thank the reviewer for drawing our attention to these publications, several of which were published after submission of our work. They are all included in our references and discussion.

Woolcott & Bergman:

https://www.liebertpub.com/doi/full/10.1089/HAM.2020.0098

Castagnetto et al:

https://www.liebertpub.com/doi/full/10.1089/ham.2020.0173

Lin et al:

https://www.liebertpub.com/doi/full/10.1089/ham.2020.0168

Pun et al:

Lower Incidence of COVID-19 at High Altitude: Facts and Confounders

https://www.liebertpub.com/doi/10.1089/ham.2020.0114

Intimayta-Escalante et al:

https://www.liebertpub.com/doi/full/10.1089/ham.2020.0133

Calvo MS:

https://academic.oup.com/ajcn/article-abstract/112/4/915/5901951

Reviewer #3: Associations of COVID-19 cases and deaths with altitude has been the subject of a number of peer-reviewed and pre-print studies since the emergence of the pandemic. While some studies conclude that likelihood of cases and/or deaths from COVID-19 inversely correlates with high altitude, other studies have not reached the same conclusion. Few studies consider population density in their analyses, which may be a relevant parameter to normalize disease susceptibility vs clustering effects.

In line with other studies, the authors do consider population density in high-altitude (HA) vs low-altitude (LA) sites in the US, and find that HA is associated with lower COVID-19 case and death rates, independent of density. This is an interesting finding by itself.

However, in addition to physiological adaptation to HA, many other variables may impact on this apparent association, in particular co-morbidies and ethnicity. While the latter are discussed in the manuscript, it would be important that these parameters are actually analyzed as part of the study, so as to reach conclusions as the role played by these factors in the observed associations.

We thank the reviewer for their review of our work and recognition of the work we did. We completely agree that other covariates such as comorbidities and ethnicity are important. We have controlled for several covariates known to impact transmission- rurality, number of persons per household state and spatial effects. Further, we discuss several of these other variables- particularly comorbidities, as a mechanism by which HA and LA differ. Further, we propose that future epidemiological studies utilize individual-level data to begin to understand the complex relationships between factors such as comorbid conditions, ethnicity, and altitude.

It would also be desirable that the authors supply the datasets used for their analyses, in a format amenable to reproduction and re-analysis by readers, including reviewers.

The datasets used in our analysis are now available at https://github.com/pchernya/Covid_Elev.

Supporting References

1. Lin, E.M., A. Goren, and C. Wambier, Letter to the Editor: Environmental Effects on Reported Infections and Death Rates of COVID-19 Across 91 Major Brazilian Cities. High Alt Med Biol, 2020.

Attachment

Submitted filename: PLOSOne Response to Reviewers.docx

Decision Letter 1

Jeffrey Shaman

30 Nov 2020

PONE-D-20-28278R1

Impact of altitude on COVID-19 infection and death in the United States: a modeling and observational study

PLOS ONE

Dear Dr. Bruns,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Note that two of the reviewers were not wholly satisfied with your response to the previous round of comments and highlight particular issues that must be addressed if this manuscript is to be accepted.

Please submit your revised manuscript by Jan 14 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Jeffrey Shaman

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript was improved after the review, and this manuscript represents further evidence of the impact of altitude and all environmental factors changed by altitude in modulating COVID. These information is of great importance for future understanding of host-virus interactions and direct further research.

Reviewer #2: I am not convinced that this paper addresses altitude effect in COVID-19 incidence/mortality when you are compromising definition of altitude or there is no altitude per se. It is like changing goal post or cut-off p-value to show significance. However, I am fine with the content if authors change title and conclusion that effect of altitude. I would suggest something like 'geographical variation' in place of 'altitude.

The literature suggested are not all incorporated/implemented by the authors although they responded they have done that.

Reviewer #3: The authors have not addressed the following request: "In addition to physiological adaptation to HA, many other variables may impact on this apparent association, in particular co-morbidies and ethnicity. While the latter are discussed in the manuscript, it would be important that these parameters are actually analyzed as part of the study, so as to reach conclusions as the role played by these factors in the observed associations."

This could be addressed at least as association analysis of COVID19 incidence/death rates with prevalence of potential co-morbidities.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Carlos Gustavo Wambier

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jan 14;16(1):e0245055. doi: 10.1371/journal.pone.0245055.r004

Author response to Decision Letter 1


2 Dec 2020

Reviewer #1: The manuscript was improved after the review, and this manuscript represents further evidence of the impact of altitude and all environmental factors changed by altitude in modulating COVID. These information is of great importance for future understanding of host-virus interactions and direct further research.

We thank the Reviewer for their time and contributions to our work.

Reviewer #2: I am not convinced that this paper addresses altitude effect in COVID-19 incidence/mortality when you are compromising definition of altitude or there is no altitude per se. It is like changing goal post or cut-off p-value to show significance. However, I am fine with the content if authors change title and conclusion that effect of altitude. I would suggest something like 'geographical variation' in place of 'altitude.

Our definition of altitude is not without precedence. We provide citations for why our definition is rigorous. Other publications, including Lin et al, as suggested by the reviewer below, do not use a discrete cut-off of 2,400m/8,000ft. While it’s true that the textbook definition of “high altitude” is a discrete value, a single numeric definition not does not represent biology, nor does it provide a comprehensive picture of how SARS-CoV-2 infection and pathogenicity change with altitude. Our modelling data clearly demonstrate a protective effect of altitude beginning at 1000m above sea level.

We agree that centroid elevation is only a proxy variable; however, we do not have access to residential addresses across the country, for instance, for which we would compute the elevation instead. If this were available, we agree it would serve as a better measure of “residence at high altitude”. However, this level of granularity is largely impractical and would fail to protect the participants’ confidentiality. We plan to continue investigating the effects of residence at high altitude using animal models and hope that this population-based study will serve as substantive motivation for subsequent experiments.

We respectfully disagree with the reviewer’s comment about “geographic variation”. Geographic variation can be captured by models with county and state effects alone, but we would lose the ability to make inferential statements regarding why certain counties are at high risk vs. low risk. By including county and state effects – which capture latent risk - in addition to measurable characteristics, we are able to make inferential statements about these characteristics, like we do with linear and non-linear associations with elevation.

However, to minimize confusion regarding word choice, we have changed the verbiage of “high altitude” to reference counties of “higher elevation; HE”. We have also amended conclusions to refer to elevation, rather than discrete HA/high altitude.

The literature suggested are not all incorporated/implemented by the authors although they responded they have done that.

The Reviewer suggested we cite Woolcot&Bergman, Castagnetto Intimayta-Escalante, and Calvo. These references are numbers 7, 3, 4, and 21 in our reference list, respectively. Pun is a review paper, not a primary report. Therefore, while we have not referenced it here, we have referenced many of the references in its citation list. We apologize for the oversight in missing Lin et al. It is now reference 5.

Reviewer #3: The authors have not addressed the following request: "In addition to physiological adaptation to HA, many other variables may impact on this apparent association, in particular co-morbidities and ethnicity. While the latter are discussed in the manuscript, it would be important that these parameters are actually analyzed as part of the study, so as to reach conclusions as the role played by these factors in the observed associations." This could be addressed at least as association analysis of COVID19 incidence/death rates with prevalence of potential co-morbidities.

We agree that race/ethnicity and the presence of co-morbidities is undoubtedly related to risk of COVID-19, however we feel it would be more epidemiologically meaningful to include those covariates for individual-level data. Because we are working with aggregated data, we initially chose to exclude these covariates to avoid introducing multicollinearity and additional ecological fallacy.

However, to investigate the Reviewer’s concern, we re-estimated our statistical models for cases recorded over the previous 30, 90, and 120 days as of 11/29/2020, adjusting for percentages of black, hispanic, and asian individuals. These data were collected for each US county during the 2013 5-year American Community Survey. Counties with more minorities tended to have higher incidence rates; however, the inclusion of race/ethnicity only slightly attenuated the linear associations with elevation, which were: -10.6% per 495m for 30-day incidence, -7.7% per 495m for 90-day incidence, and -6.5% per 495m for 120-day incidence. All associations remained statistically significant at an alpha level of 0.01. In addition, models with race/ethnicity explain an additional 1%, 3%, and 4% variability (for 30, 90, 120-day incidence, respectively), relative to what we report in our manuscript (Supplementary Table 1). Taken together, we feel we should keep the statistical models reported in the text targeted towards our stated hypothesis, which covered rurality and density inside the household, but did not cover county demographics.

Decision Letter 2

Jeffrey Shaman

22 Dec 2020

Impact of altitude on COVID-19 infection and death in the United States: a modeling and observational study

PONE-D-20-28278R2

Dear Dr. Bruns,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Jeffrey Shaman

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: I am fine with the changes. The altitude to elevation is not consistent throughout the the manuscript.

Reviewer #3: The authors have provided a reasonable explanation for not conducting in the current study the requested co-morbidity association analyses.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

Acceptance letter

Jeffrey Shaman

23 Dec 2020

PONE-D-20-28278R2

Impact of altitude on COVID-19 infection and death in the United States: a modeling and observational study

Dear Dr. Bruns:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Jeffrey Shaman

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Unprojected choropleth map of U.S. county centroids colored by elevation in meters.

    Elevation patterns based on county centroids closely represent elevation patterns of the continental U.S.

    (DOCX)

    S2 Fig. COVID-19 infection and death in matched high and low altitude counties with removal of counties with infection and death counts of zero.

    A) Mean COVID-19 cumulative per capita incidence per 100,000 population. B) Mean COVID-19 cumulative per capita death per 100,000 population. C) COVID-19 case mortality in high and low altitude counties of similar population density. N = 33 for high altitude and N = 26 for low altitude counties. *p<0.05 by one-sided t-test.

    (DOCX)

    S1 Table. Akaike Information Criterion (AIC) and percent deviance explained in parentheses for the statistical models considered.

    Smaller AIC and larger percent deviance explained constitutes the preferred model.

    (DOCX)

    S1 File

    (DOCX)

    Attachment

    Submitted filename: PLOSOne Response to Reviewers.docx

    Data Availability Statement

    Data are available in GitHub: https://github.com/pchernya/Covid_Elev.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES